Your browser doesn't support javascript.
loading
Taste-Masked Flucloxacillin Powder Part 1: Optimisation of Fabrication Process Using a Mixture Design Approach.
Yoo, Okhee; Salman, Sam; von Ungern-Sternberg, Britta S; Lim, Lee Yong.
Afiliação
  • Yoo O; Pharmacy, School of Allied Health, University of Western Australia, Perth, WA 6009, Australia.
  • Salman S; Clinical Pharmacology and Toxicology Unit, PathWest Laboratory Medicine, Perth, WA 6009, Australia.
  • von Ungern-Sternberg BS; Medical School, The University of Western Australia, Perth, WA 6009, Australia.
  • Lim LY; Medical School, The University of Western Australia, Perth, WA 6009, Australia.
Pharmaceuticals (Basel) ; 16(8)2023 Aug 17.
Article em En | MEDLINE | ID: mdl-37631086
It is extremely challenging to formulate age-appropriate flucloxacillin medicines for young children, because flucloxacillin sodium (FS) has a lingering, highly bitter taste, dissolves quickly in saliva, and requires multiple daily dosing at relatively large doses for treating skin infections. In this paper, we describe a promising taste-masked flucloxacillin ternary microparticle (FTM) formulation comprising FS, Eudragit EPO (EE), and palmitic acid (PA). To preserve the stability of the thermolabile and readily hydrolysed flucloxacillin, the fabrication process employed a non-aqueous solvent evaporation method at ambient temperature. Optimisation of the fabrication method using a mixture design approach resulted in a robust technique that generated stable and reproducible FTM products. The optimised method utilised only a single solvent evaporation step and minimal amounts of ICH class III solvents. It involved mixing two solution phases-FS dissolved in ethanol:acetone (1:4 v/v), and a combination of EE and PA dissolved in 100% ethanol-to give a ternary FS:EE:PA system in ethanol: acetone (3:1 v/v). Solvent evaporation yielded the FTMs containing an equimolar ratio of FS:EE:PA (1:0.8:0.6 w/w). The fabrication process, after optimisation, demonstrated robustness, reproducibility, and potential scalability.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália
...